| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001719 | EBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10006549 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10008067 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10008068 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30003991 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30079115 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30087748 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30081211 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30081546 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30082146 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EGFR |
|---|---|
| DrugBank ID | DB01259 |
| Drug Name | Lapatinib |
| Target ID | BE0000767 |
| UniProt ID | P00533 |
| Regulation Type | antagonist |
| PubMed IDs | 12214266; 14633707; 14737100; 14751502; 14967461; 15163842; 15374980; 20658522; 16894399; 20110044; 18803986; 11752352 |
| Citations | Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002 Sep 12;21(41):6255-63.@@Grana TM, Sartor CI, Cox AD: Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res. 2003 Nov 15;63(22):7807-14.@@Xia W, Liu LH, Ho P, Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 2004 Jan 22;23(3):646-53.@@Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI: Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52.@@Langer CJ: Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002.@@Burris HA 3rd: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9 Suppl 3:10-5.@@Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004 Sep 15;64(18):6652-9.@@Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez JA: Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J Cell Physiol. 2011 Jan;226(1):52-7. doi: 10.1002/jcp.22333.@@Johnston SR, Leary A: Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006 Jul;42(7):441-53.@@Tevaarwerk AJ, Kolesar JM: Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029.@@Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Quinazolinamines |
| SMILES | CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1 |
| Pathways | |
| PharmGKB | PA152241907 |
| ChEMBL | CHEMBL554 |
